Immunohistochemistry of the tumor tissues showed that TM4SF5 expression was not different among treatments, but Slamf7 expression was more restricted to non-tumor regions in vehicle-treated animals and more widely dispersed, even in smaller tumor lesions, in TSI-treated animals, indicating more SLAMF7-positive hepatocytes and less aggressive HCC growth (Fig. 6d). The gene discussed is TM4SF5; the disease is neoplasm.